CClinicalTrials.gg
CompletedNCT02869659VEGGIEUpdated Dec 31, 2020

Valued EpiGenetic Glycemic ImprovEments Through Weight Loss

An interventional study of Weight Loss Group and Delayed Weight Loss in Obesity and Pre-diabetes, sponsored by Wake Forest University Health Sciences. Completed at 1 site in United States. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-12-31.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Study summary

This randomized controlled clinical trial will use methylomic and transcriptomic profiling to examine the effects of a weight loss intervention on the cholesterol metabolism gene network in monocytes and adipocytes and investigate the longitudinal relationship between these modifications and glycemic improvements.

Read the detailed description

The investigators plan to recruit a total of 200 middle-aged (40-65 years) obese (BMI=30-39.9 kg/m2), sedentary, pre-diabetic participants who will be randomized to either a 18-week dietary weight loss (n=100) followed by a 8-week transition and then 26 weeks of maintenance (Weight Loss group) or a delayed weight loss (Control group, n=100) intervention.

During the screening visit, eligible participants who provided informed consent will complete a 3-day food record and then start a 3-day run-in period using the Medifast® meal replacement products to be used for the weight loss intervention. At the next visit the participant will meet with the Registered Dietitian (RD) to undergo an assessment of Readiness to Change (18). All participants must be approved for eligibility by the RD based on her clinical judgment of likelihood of success for weight loss, likelihood of compliance to the Medifast® meal plan, and willingness to be randomized to either group.

Control/Delayed Weight Loss Group: (18 weeks) Participants randomized to the delayed weight loss intervention (n=100) will serve as a no-weight loss control to the weight loss group during the first 18 weeks of the study. During the control (18 weeks) phase these participants will receive a monthly phone call visit from staff to maintain contact and interest in the study. At the end of the initial 18 weeks participants will complete all follow up assessments prior to being offered the opportunity to participate in a weight loss program. This weight loss program will involve 18 weekly, group dietary and exercise sessions led by the study staff in which participants will follow a modified Diabetes Prevention Program. Participants will be given an individual introduction session to the weight loss program by study staff and will be guided by the RD on their food purchasing and preparation of their meals, but no meal replacements or supplements will be provided.

Weight Loss group: Phase 1 (18 weeks): Participants assigned to this group will undergo a dietary intervention for the first 18 weeks of the study designed to elicit an approximate 8-10% weight loss. The intervention will incorporate partial meal replacements, nutrition education, and some behavior modification.

This level of weight loss will be achieved through the combination of a partial meal replacement (MR) program and individual and group nutrition/behavioral counseling. Participants will be provided with and asked to consume 4 Medifast® MR per day. All participants will follow the Medifast Achieve TM 4 \& 2 \& 1 Plan® which includes the 4 MR products per day, with the addition of 2 Lean and Green™ Meals and 1 Healthy Snack. The Lean and Green™ Meals will be prepared by the participants and each will consist of 5-7 oz. lean protein, 3 servings of non-starchy vegetables and up to 2 servings of healthy fat. The Healthy Snack will consist of one serving of fruit, dairy, or grain. Each MR from Medifast® contains \~90-110 kcals and 10-15 g protein. Participants will be given an individual introduction on the meal plan prior to starting and will be guided by the RD on their food purchasing and preparation of the other Lean and Green TM meals. They are encouraged to consume only what is approved on the Medifast Achieve TM 4 \& 2 \& 1 Plan®.

Phase 2 (8 weeks): After completion of the active weight loss phase, participants in this group will attend bimonthly group meetings to discuss increasing their activity. The goal is for participants to slowly increase their activity to 150 minutes per week and then continue at 150 minutes per week to help them maintain their weight. Activity logs will be dispensed and topics such as tracking activity, finding time for fitness and getting active will be discussed.

Participants will have the option to transition off the meal replacements and potentially continue on a select few during the transition phase. Additional dietary guidance will be available to help participants transition off MR and maintain their weight. The RD will calculate individual maintenance calorie goals to be discuss with participants at a brief individual session prior to starting the transition phase. At this session an introduction to the transition phase and information on how to track their activity will also be discussed.

Phase 3 (26 weeks): After completion of phase 2, participants will be called monthly for 26 weeks and then asked to return for a maintenance visit at the end of the 52 weeks from study start. Participants will be offered an optional session with a staff member at the time of their exit to discuss long term goals and strategies and provide closure.

02

Conditions studied

  • Obesity
  • Pre-diabetes

Keywords

  • obesity
  • pre-diabetes
  • overweight
  • lifestyle change
  • glucose
03

In context

Prediabetic State

999 studies on the registry are indexed under Prediabetic State; 238 are open to participants now.

This study's enrollment of 138 is above the median of 65 across 844 interventional studies indexed under Prediabetic State.

Browse Prediabetic State studies →

Lead sponsor

Wake Forest University Health Sciences is the lead sponsor of 1,320 studies on the registry; 199 are open to participants now.

Of its 323 completed or terminated interventional studies of FDA-regulated products, 243 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • BMI=30-45.0 kg/m2 OR BMI 27-30, if waist circumference is ≥ 40in in men or ≥ 35in in women
  • Sedentary for past 6 mos (\<20 min; 2 d/wk of resistance or aerobic exercise)
  • Normal cognitive function:

Greater than 12 years education:

Caucasian - MOCA ≥ 24 African American/Hispanic/Other- MOCA ≥ 22

12 years or less education: Caucasian- MOCA ≥22 African American/Hispanic/Other- MOCA ≥20

  • No evidence of clinical depression
  • Fasting blood glucose 100-125 mg/dl OR Hemoglobin A1c 5.7% - 6.4%
  • No contraindications for participation in weight loss
  • Able to provide own transportation to study visits and intervention
  • Approved for participation by Medical Director
  • Negative pregnancy test or confirmed post-menopausal/surgically sterile status (Women Only)
  • Not involved in any other research study
  • Willing to provide informed consent

Exclusion criteria

Exclusion Criteria:

  • Weight loss (±5%) in past 6 months
  • Uncontrolled arrhythmias
  • Cancer requiring treatment in past year, except non-melanoma skin cancers
  • Regular smoker (>1 cigarette/day) or heavy drinker (>9 alcoholic drinks/wk) within past year
  • Insulin dependent or uncontrolled diabetes (FBG>126 mg/dl) OR (Hemoglobin A1c 6.5% or greater)
  • Uncontrolled hypertension (BP>160/90 mmHg)
  • Elevated triglyceride (TG>400 mg/dl)
  • Clinically evident liver disease, kidney disease, edema or anemia
  • Past or current ischemic heart disease, uncontrolled angina, heart failure, PAD, stroke, chronic respiratory disease, endocrine or metabolic disease, neurological or hematological disease
  • Regular use growth/steroid hormones, including estrogen replacement, weight loss medications, diabetes medications including insulin and/or blood thinners
  • History of any type of bariatric or weight loss surgery or bilateral oophorectomy requiring long term hormone replacement therapy use
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
138 participants (actual)

Study arms

  • Active comparator
    Control/Delayed Weight Loss Group

    Control/Delayed Weight Loss Group: (18 weeks) Participants randomized to the delayed weight loss intervention (n=100) will serve as a no-weight loss control to the weight loss group during the first 18 weeks of the study. During the control (18 weeks) phase these participants will receive a monthly phone call visit from staff to maintain contact and interest in the study. At the end of the initial 18 weeks participants will complete all follow up assessments prior to being offered the opportunity to participate in a weight loss program. No outcome data will be collected at the end of the delayed weight loss phase.

    Behavioral: Delayed Weight Loss

  • Experimental
    Weight Loss Group

    Weight Loss group: Phase 1 (18 wks): Participants assigned to this group will undergo a dietary intervention for the first 18 weeks of the study. This level of weight loss will be achieved through the combination of a partial meal replacement (MR) program and individual and group nutrition/behavioral counseling. Participants will be provided with and asked to consume 4 Medifast® MR per day. Phase 2 (8 wks): After completion of the active weight loss phase, participants in this group will attend bimonthly group meetings to discuss increasing their activity. Phase 3 (26 wks): After completion of phase 2, participants will be called monthly for 26 weeks and then asked to return for a maintenance visit at the end of the 52 weeks from study start.

    Behavioral: Weight Loss Group

Interventions

  • BehavioralWeight Loss Group

    All participants will follow the Medifast Achieve TM 4 \& 2 \& 1 Plan® which includes the 4 MR products per day, with the addition of 2 Lean and Green™ Meals and 1 Healthy Snack

  • BehavioralDelayed Weight Loss

    18 weekly, group dietary and exercise sessions led by the study staff in which participants will follow a modified Diabetes Prevention Program

06

What researchers measure

Primary outcomes

  1. Chang in Epigengene score (and related individual transcriptional and methylation measures)

    The eigengene score is defined as the first principal component of a transcriptional network.

    Time frame: baseline and 18 weeks

Secondary outcomes

  1. change in glucose tolerance

    A 2-hr OGTT will be performed to assess changes in glucose tolerance and insulin responses to the glucose challenge. Blood samples will be drawn before and after (30, 60, 90, and 120 min) a 75-g glucose ingestion for the determination of plasma glucose and insulin.

    Time frame: baseline and 18 weeks

  2. change in homeostatic model assessment (HOMA) estimates of insulin resistance

    A 2-hr OGTT will be performed to assess changes in glucose tolerance and insulin responses to the glucose challenge. Blood samples will be drawn before and after (30, 60, 90, and 120 min) a 75-g glucose ingestion for the determination of plasma glucose and insulin. An estimate of insulin sensitivity by the homeostasis model assessment (HOMA) score will be calculated with the formula: fasting plasma insulin (μU/ml) × glucose (mmol/l)/22.5 (25). Glucose and insulin areas will be determined using Tai's model(26): ½×30×(y0min+2y30min+2y60min+2y90min+y120min), where y represents insulin or glucose values at the different time points.

    Time frame: baseline and 18 weeks

07

Study locations

1 site
  • Wake Forest Health Sciences
    Winston-Salem, North Carolina 27157, United States
08

References and documents

Study documents

  • Informed consent form · Jan 13, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02869659
Lead sponsor
Wake Forest University Health Sciences
Collaborators
Medifast, Inc., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Responsible party
Sponsor
First posted
Aug 17, 2016
Start date
Nov 1, 2016
Primary completion
Jul 29, 2020
Completion
Dec 2, 2020
Last update
Dec 31, 2020

Study contacts

Jingzhong Ding, PhD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion